Filter by Event: ESCMID Global 2024
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalised with Bacterial Pneumonia in Western and Eastern Europe (SENTRY Program; 2021–2022)
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalised with Bacterial Pneumonia in Western and Eastern Europe (SENTRY Program; 2021–2022). Lead Author: Helio S. Sader, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #3220
Activity of gepotidacin against Klebsiella pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in Europe and adjacent regions (2019–2022).
Activity of gepotidacin against <i>Klebsiella pneumoniae<i>, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in Europe and adjacent regions (2019–2022). Lean Author: Rodrigo Mendes, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #P1441
Activity of aztreonam-avibactam and comparator agents against a global collection of metallo-β-lactamase-producing Enterobacterales
Activity of aztreonam-avibactam and comparator agents against a global collection of metallo-β-lactamase-producing Enterobacterales. Lead Author: Mariana Castanheira, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #1439
β-lactam resistance mechanisms in baseline Enterobacterales from the REVISIT and ASSEMBLE aztreonam-avibactam Phase 3 clinical trials
β-lactam resistance mechanisms in baseline Enterobacterales from the REVISIT and ASSEMBLE aztreonam-avibactam Phase 3 clinical trials. Lead Author: Rodrigo Mendes at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #P1824
High-level plazomicin exposure selects for mutations in fusA, ratA, and a novel two-component system in Morganella morganii
High-level plazomicin exposure selects for mutations in fusA, ratA, and a novel two-component system in <i>Morganella morganii</i>. Lead Author: John H. Kimbrough, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #P1694
Activity of cefiderocol against carbapenem non-susceptible Enterobacterales, including molecularly characterized clinical isolates causing infection in hospitals in European and adjacent regions (2020–2022)
Activity of cefiderocol against carbapenem non-susceptible Enterobacterales, including molecularly characterized clinical isolates causing infection in hospitals in European and adjacent regions (2020–2022). Lead Author: Rodrigo Mendes, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #P1406
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against a Large Collection of Stenotrophomonas maltophilia Isolates Collected in Europe, Asia, and Latin America (2018–2023)
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against a Large Collection of <i>Stenotrophomonas maltophilia</i> Isolates Collected in Europe, Asia, and Latin America (2018–2023). Lead Author: Helio S. Sader, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #1357
In vitro Activity of Gepotidacin and Comparator Agents Against a Collection of Klebsiella pneumoniae Urine Isolates Collected from Europe during 2019–2022
In vitro Activity of Gepotidacin and Comparator Agents Against a Collection of <i>Klebsiella pneumoniae</i> Urine Isolates Collected from Europe during 2019–2022. Presenting Author: S. J. Ryan Arends, Ph.D., at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #2433
Use of Voriconazole to Predict Susceptibility and Resistance to Isavuconazole for Aspergillus fumigatus by Using the CLSI Methods and Interpretive Criteria
Use of Voriconazole to Predict Susceptibility and Resistance to Isavuconazole for <i>Aspergillus fumigatus</i> by Using the CLSI Methods and Interpretive Criteria. Lead Author: Mariana Castanheira, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #2930
Analysis of Resistance to Oral Standard-of-Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected in Europe in 2022
Analysis of Resistance to Oral Standard-of-Care Antibiotics for Urinary Tract Infections Caused By <i>Escherichia coli</i> and <i>Staphylococcus saprophyticus</i> Collected in Europe in 2022. Presenting Author: S. J. Ryan Arends at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #MTV11-06
Activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2022)
Activity of cefiderocol against carbapenem-resistant <i>Acinetobacter baumannii-calcoaceticus</i> complex, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2022). Lead Author: Rodrigo Mendes, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #MTV0604
Rezafungin Activity Against Echinocandin–Nonwildtype Candida glabrata Clinical Isolates Collected in European countries (2014–2021)
Rezafungin Activity Against Echinocandin–Nonwildtype <i>Candida glabrata</i> Clinical Isolates Collected in European countries (2014–2021). Lead Author: Mariana Castanheira, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Activity of cefiderocol against carbapenem non-susceptible Pseudomonas aeruginosa, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2022)
Activity of cefiderocol against carbapenem non-susceptible <i>Pseudomonas aeruginosa</i>, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2022). Lead Author: Rodrigo Mendes, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #MTV0605
Activity of gepotidacin against molecularly characterized Klebsiella pneumoniae isolates from patients with urinary tract infections in Europe and adjacent regions (2019–2022)
Activity of gepotidacin against molecularly characterized Klebsiella pneumoniae isolates from patients with urinary tract infections in Europe and adjacent regions (2019–2022). Lead Author: Rodrigo Mendes at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #P2479
Proposed zosurabalpin broth microdilution quality control ranges using Clinical and Laboratory Standards Institute M23 Tier 2 criteria
Proposed zosurabalpin broth microdilution quality control ranges using Clinical and Laboratory Standards Institute M23 Tier 2 criteria. Lead Author: Michael Huband, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #P2452
Genetic relationship and mechanisms contributing to reduced gepotidacin susceptibility in isolates from EAGLE- 2/EAGLE-3 clinical trials for uncomplicated urinary tract infections
Genetic relationship and mechanisms contributing to reduced gepotidacin susceptibility in isolates from EAGLE-2/EAGLE-3 clinical trials for uncomplicated urinary tract infections. Presenting Author: Rodrigo Mendes at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #1052
Bloodstream Infections in European Hospitals: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2021–2022)
Bloodstream Infections in European Hospitals: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2021–2022). Lead Author: Helio S. Sader, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
